A Prospective, Post-market, Multi-center Feasibility Study of the BioDuct® Meniscal Repair Device

Knee Meniscus Tear Clinical Trial

Official title:

This Study Will be a Prospective, Non-randomized Evaluation of the Change Between Preoperative and Postoperative Outcomes for Those Who Receive the BioDuct® Device Meniscal Repair Device.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01270919
• Other study ID #: 73
• Status: Terminated
• Phase: N/A
• First received: January 4, 2011
• Last updated: May 22, 2014
• Start date: November 2010
• Est. completion date: May 2011

Study information

• Verified date: May 2014
• Source: Stryker Orthopaedics
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardUnited States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To demonstrate repair of the meniscus at 6 months, as evaluated by MRI, will be observed; and clinical qualitative assessments will improve from preoperative to postoperative time points with the BioDuct® Meniscal Repair Device.

Description:

To demonstrate repair of the meniscus 6 months postimplantation of the BioDuct® Meniscal Repair Device, utilizing MRI.

To evaluate clinical success by comparing the following qualitative criteria at 2 years postoperative to preoperative findings: effusion, swelling, pain, catching, locking, focal joint line pain and mechanical symptoms, if present preoperative. Clinical success is defined as no worsening for any of these criteria and improvement in at least one of these criteria.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: May 2011
• Est. primary completion date: May 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• A. Patient has signed an IRB approved, study specific Informed Patient Consent Form.

• B. Patient is a male or non-pregnant female age 45 years or younger at time of study device implantation.

• C. Patient is a candidate for repair of one longitudinal vertical tear (bucket handle) fully located in the red-white (vascular-avascular) zone of the meniscus (3-5 mm from the synovial-meniscus junction) or repair of one longitudinal vertical tear (bucket handle) primarily located in the red-white zone of the meniscus, but partially (< 30% of total length) extending into the red zone (< 3 mm from the synovial-meniscus junction) and/or into the white zone (> 5 mm from the synovial-meniscus junction).

• D. Patient does not require more than three BioDuct® Meniscal Repair Devices for the meniscal tear.

• E. Patient requires suture only for fixation at the site where the study device will be used.

• F. Patient is willing and able to comply with postoperative scheduled MRI and clinical evaluations and rehabilitation.

Exclusion Criteria:

• G. Patient has a Body Mass Index (BMI) > 35.

• H. Patient has an active or suspected latent infection in or about the affected knee joint at time of study device implantation.

• I. Patient has horizontal, transverse, degenerative complex tears.

• J. Patient has ACL and/or PCL deficiencies within the operative knee and is not undergoing concomitant repair of these deficiencies.

• K. Patient requires bilateral meniscal repair.

• L. Patient requires meniscectomy.

• M. Patient presents with abnormal degenerative osteoarthritis of the joint [e.g. International Cartilage Repair Society (ICRS) Grade III or higher and/or Modified Outerbridge Grade III or higher].

• N. Patient has undergone previous meniscal repair to the operative knee.

• O. Patient has a knee joint with greater than 5º anatomic axis misalignment.

• P. Patient has active synovitis.

• Q. Patient is a prisoner.

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Knee Meniscus Tear

Intervention

Device:
• BioDuct Meniscal Repair Device
The BioDuct® Meniscal Repair Device is a small, cannulated, arthroscopically implanted, bioabsorbable conduit that has length sizes of 5, 7 and 9 mm. Based on the concept of trephination for treating meniscal tears in the red-white zone, the BioDuct® Meniscal Repair Device is designed to create a vascular access channel between the vascular-rich and cell-rich synovium and the meniscal tear. This channel allows for the flow of blood from the vascular to the avascular tissue to promote repair of the meniscus. The BioDuct® Meniscal Repair Device is not used across meniscal tears, like other fixation devices. The BioDuct® Meniscal Repair Device is used in conjunction with suturing and helps provide vascular access, while the sutures help provide fixation. Based on the Inclusion Criteria of this protocol, there can be a maximum of three BioDuct® Meniscal Repair Devices utilized for the meniscal tear.

Locations

Country	Name	City	State
United States	Jack Farr, M.D.	Indianapolis	Indiana
United States	Randall Holcomb	Memphis	Tennessee
United States	Jason Scopp, M.D.	Salisbury	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Stryker Orthopaedics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To Demonstrate Repair of the Meniscus 6 Months Post-implantation of the BioDuct® Meniscal Repair Device, Utilizing MRI. To Evaluate Clinical Success Using Postoperative Qualitative Criteria, as Compared to Preoperative Findings.		2 years	No
Secondary	To Evaluate the Change in Outcomes From the Preoperative Time Point to Postoperative Time Points in Cases Implanted With the BioDuct® Meniscal Repair Device Using the SF-12, VAS Pain, WOMET and IKDC Subjective Knee Evaluation.		Postoperative compared to preoperative	No